Jinghua Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jinghua Wang has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Chengfu Xu
Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
6 shared publications Chaohui Yu
Department of Gastroenterology the First Affiliated Hospital Zhejiang University School of Medicine Hangzhou China
2 shared publicationsShenghui Chen
Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
2 shared publications- Shenghui Chen
Department of Gastroenterology, Affiliated Hangzhou First People’s Hospital, School of Medicine, Westlake University, Zhejiang, China
2 shared publications Yishu Chen
Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
2 shared publications- Zhening Liu
Department of Gastroenterology, The First Affiliated Hospital Zhejiang University School of Medicine Hangzhou Zhejiang China
2 shared publications
Latest Publications
- 13 July 2025
- Published by Wiley in Helicobacter
- Vol. 30 (4) , e70056
Vonoprazan Improves Efficacy of Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Multicenter Randomized Controlled Trial
Background: Rescue treatment for non‐naive patients with persistent Helicobacter pylori (H. pylori) infection is lacking, especially in areas where tetracycline is unavailable. This trial aimed to evaluate the efficacy and safety of replacing proton pump inhibitor (PPI) with potassium‐competitive acid blocker (P‐CAB) in bismuth quadruple therapy (BQT) containing amoxicillin and furazolidone as rescue therapy.Materials and Methods: We conducted a prospective, open‐label, noninferiority randomized controlled trial at six institutions in eastern China. A total of 444 patients with a history of H. pylori treatment failure were enrolled and randomly assigned in a 1:1 ratio to either the 14‐day P‐CAB‐BQT group (vonoprazan 20 mg, colloidal bismuth 200 mg, amoxicillin 1000 mg and furazolidone 100 mg, all given twice daily) or the 14‐day PPI‐BQT group (rabeprazole 10 mg given twice daily, and the same dose of three other drugs as the 14‐day P‐CAB‐BQT group). The primary endpoint was the eradication rate assessed by 13C urea breath test. The secondary endpoints were adverse events and compliance.Results: H. pylori eradication rates of PPI‐BQT versus P‐CAB‐BQT group were 83.8% versus 91.9% in the intention‐to‐treat (ITT) analysis (treatment difference: 8.1%; 95% CI: 2.1%–14.1%; non‐inferiority p < 0.001, p‐value for difference = 0.008); 86.1% versus 95.8% in the modified ITT (MITT) analysis (treatment difference: 9.7%; 95% CI: 4.4%–15.0%; non‐inferiority p < 0.001, p‐value for difference < 0.001); and 86.3% versus 95.6% in the per‐protocol (PP) analysis (treatment difference: 9.3%; 95% CI: 3.8%–14.8%; non‐inferiority p < 0.001, p‐value for difference < 0.001). The P‐CAB‐BQT regimen was shown to be non‐inferior to the PPI‐BQT regimen and yielded higher eradication rates across all analysis populations (ITT, MITT, and PP). The overall frequency of adverse events (27.9% and 34.2%, p = 0.151) and compliance (93.7% and 94.6%, p = 0.686) were similar between PPI and P‐CAB groups. Among the patients suspected of drug‐induced fever (8.6% and 7.2%, p = 0.597), 82.9% experienced fever after administration of furazolidone for > 10 days. The eradication rates were not affected by prior choice of antibiotics and the number of treatment attempts.Conclusions: The 14‐day P‐CAB‐BQT therapy containing amoxicillin and furazolidone provided a satisfactory eradication rate and a good safety profile as rescue treatment for H. pylori eradication, regardless of prior choice of antibiotics and the number of treatment attempts. Shortening the treatment course to 10–11 days could prevent the majority of drug‐induced fevers.
- 13 July 2025
- Published by Wiley in Helicobacter
- Vol. 30 (4) , e70056
Vonoprazan Improves Efficacy of Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Multicenter Randomized Controlled Trial
Background: Rescue treatment for non‐naive patients with persistent Helicobacter pylori (H. pylori) infection is lacking, especially in areas where tetracycline is unavailable. This trial aimed to evaluate the efficacy and safety of replacing proton pump inhibitor (PPI) with potassium‐competitive acid blocker (P‐CAB) in bismuth quadruple therapy (BQT) containing amoxicillin and furazolidone as rescue therapy.Materials and Methods: We conducted a prospective, open‐label, noninferiority randomized controlled trial at six institutions in eastern China. A total of 444 patients with a history of H. pylori treatment failure were enrolled and randomly assigned in a 1:1 ratio to either the 14‐day P‐CAB‐BQT group (vonoprazan 20 mg, colloidal bismuth 200 mg, amoxicillin 1000 mg and furazolidone 100 mg, all given twice daily) or the 14‐day PPI‐BQT group (rabeprazole 10 mg given twice daily, and the same dose of three other drugs as the 14‐day P‐CAB‐BQT group). The primary endpoint was the eradication rate assessed by 13C urea breath test. The secondary endpoints were adverse events and compliance.Results: H. pylori eradication rates of PPI‐BQT versus P‐CAB‐BQT group were 83.8% versus 91.9% in the intention‐to‐treat (ITT) analysis (treatment difference: 8.1%; 95% CI: 2.1%–14.1%; non‐inferiority p < 0.001, p‐value for difference = 0.008); 86.1% versus 95.8% in the modified ITT (MITT) analysis (treatment difference: 9.7%; 95% CI: 4.4%–15.0%; non‐inferiority p < 0.001, p‐value for difference < 0.001); and 86.3% versus 95.6% in the per‐protocol (PP) analysis (treatment difference: 9.3%; 95% CI: 3.8%–14.8%; non‐inferiority p < 0.001, p‐value for difference < 0.001). The P‐CAB‐BQT regimen was shown to be non‐inferior to the PPI‐BQT regimen and yielded higher eradication rates across all analysis populations (ITT, MITT, and PP). The overall frequency of adverse events (27.9% and 34.2%, p = 0.151) and compliance (93.7% and 94.6%, p = 0.686) were similar between PPI and P‐CAB groups. Among the patients suspected of drug‐induced fever (8.6% and 7.2%, p = 0.597), 82.9% experienced fever after administration of furazolidone for > 10 days. The eradication rates were not affected by prior choice of antibiotics and the number of treatment attempts.Conclusions: The 14‐day P‐CAB‐BQT therapy containing amoxicillin and furazolidone provided a satisfactory eradication rate and a good safety profile as rescue treatment for H. pylori eradication, regardless of prior choice of antibiotics and the number of treatment attempts. Shortening the treatment course to 10–11 days could prevent the majority of drug‐induced fevers.
- Open Access
- 28 June 2022
- Published by Wiley in Canadian Journal of Gastroenterology and Hepatology
- Vol. 2022, 1-8
Association Between Serum Afamin Levels with Nonalcoholic Associated Fatty Liver Disease
Afamin is a member of the hepatokine that are strongly associated with various metabolic diseases. The relationship between afamin and nonalcoholic fatty liver disease (NAFLD) remains unclear. This study aimed to explore the correlation between serum afamin levels and NAFLD. We analyzed 88 NAFLD patients and 88 age- and sex-matched healthy controls who took their health examinations at the First Affiliated Hospital, Zhejiang University School of Medicine. The association was further confirmed in 22 biopsy-confirmed NAFLD patients and 36 healthy controls. Serum afamin levels were evaluated using an enzyme-linked immunosorbent assay (ELISA). NAFLD patients had significantly higher serum afamin levels than the healthy controls (14.79 ± 5.04 mg/L versus 10.83 ± 3.24 mg/L; ). Serum afamin levels were positively correlated with metabolic parameters including the body mass index, waist circumference, systolic blood pressure, liver enzymes, and lipid profiles. A multiple regression analysis showed that serum afamin levels were independently related to the risk of NAFLD (OR: 1.289, 95% CI, 1.141–1.456; ). The receiver operating characteristic (ROC) analysis showed that the area under curve (AUC) of serum afamin plus the BMI for detecting NAFLD was 0.878. In participants with liver biopsies, the serum afamin plus the BMI detected NAFLD with an AUC of 0.758. In conclusion, serum afamin levels were positively associated with prevalence and risk of NAFLD, and serum afamin plus the BMI had a high diagnostic performance for NAFLD. This study provides epidemiological evidence of afamin in NAFLD.
- 28 June 2022
- Published by Wiley in Canadian Journal of Gastroenterology and Hepatology
- Vol. 2022, 1-8
Open AccessAssociation Between Serum Afamin Levels with Nonalcoholic Associated Fatty Liver Disease
Afamin is a member of the hepatokine that are strongly associated with various metabolic diseases. The relationship between afamin and nonalcoholic fatty liver disease (NAFLD) remains unclear. This study aimed to explore the correlation between serum afamin levels and NAFLD. We analyzed 88 NAFLD patients and 88 age- and sex-matched healthy controls who took their health examinations at the First Affiliated Hospital, Zhejiang University School of Medicine. The association was further confirmed in 22 biopsy-confirmed NAFLD patients and 36 healthy controls. Serum afamin levels were evaluated using an enzyme-linked immunosorbent assay (ELISA). NAFLD patients had significantly higher serum afamin levels than the healthy controls (14.79 ± 5.04 mg/L versus 10.83 ± 3.24 mg/L; ). Serum afamin levels were positively correlated with metabolic parameters including the body mass index, waist circumference, systolic blood pressure, liver enzymes, and lipid profiles. A multiple regression analysis showed that serum afamin levels were independently related to the risk of NAFLD (OR: 1.289, 95% CI, 1.141–1.456; ). The receiver operating characteristic (ROC) analysis showed that the area under curve (AUC) of serum afamin plus the BMI for detecting NAFLD was 0.878. In participants with liver biopsies, the serum afamin plus the BMI detected NAFLD with an AUC of 0.758. In conclusion, serum afamin levels were positively associated with prevalence and risk of NAFLD, and serum afamin plus the BMI had a high diagnostic performance for NAFLD. This study provides epidemiological evidence of afamin in NAFLD.
- Open Access
Prevalence and risk factors of hyperuricaemia in non-obese Chinese: a single-centre cross-sectional study
Objectives: Hyperuricaemia is closely related to metabolic diseases and is receiving increasing attention from all over the world. This study aimed to investigate the prevalence and factors associated with hyperuricaemia in non-obese Chinese population. Design: Retrospective cross-sectional study. Setting: A large general hospital that can provide health check-ups in Hangzhou, China. Participants: A total of 5731 apparently healthy Chinese adults (2349 men and 3382 women) who took their health check-ups during the year of 2019. Exclusion criteria: (1) those with body mass index ≥24 kg/m 2 ; (2) those with incomplete anthropometric and biochemical data; (3) those with a history of malignancy and (4) those under urate-lowering treatment. Primary and secondary outcome measures: The prevalence and factors associated with hyperuricaemia in non-obese Chinese adults. Results: Of the 5731 non-obese subjects enrolled, 538 (9.4%) were identified as having hyperuricaemia, specifically 16.3% in men and 4.6% in women. The prevalence of hyperuricaemia markedly increased in women aged above 50 years. The prevalence of hyperuricaemia was significantly higher in metabolically unhealthy participants with normal weight than in metabolically healthy participants with normal weight. Participants with hyperuricaemia showed a higher prevalence of metabolic syndrome and fatty liver disease than participants with normouraemia. Age, waist circumference, estimated glomerular filtration rate, blood urea nitrogen, excessive drinking and fatty liver were associated with hyperuricaemia in both genders. Conclusion: The prevalence of hyperuricaemia was 9.4% in non-obese Chinese adults. Non-obese participants with hyperuricaemia also showed multiple metabolic disorders. We suggest that clinicians pay attention to serum uric acid level in non-obese patients.
Open AccessPrevalence and risk factors of hyperuricaemia in non-obese Chinese: a single-centre cross-sectional study
Objectives: Hyperuricaemia is closely related to metabolic diseases and is receiving increasing attention from all over the world. This study aimed to investigate the prevalence and factors associated with hyperuricaemia in non-obese Chinese population. Design: Retrospective cross-sectional study. Setting: A large general hospital that can provide health check-ups in Hangzhou, China. Participants: A total of 5731 apparently healthy Chinese adults (2349 men and 3382 women) who took their health check-ups during the year of 2019. Exclusion criteria: (1) those with body mass index ≥24 kg/m 2 ; (2) those with incomplete anthropometric and biochemical data; (3) those with a history of malignancy and (4) those under urate-lowering treatment. Primary and secondary outcome measures: The prevalence and factors associated with hyperuricaemia in non-obese Chinese adults. Results: Of the 5731 non-obese subjects enrolled, 538 (9.4%) were identified as having hyperuricaemia, specifically 16.3% in men and 4.6% in women. The prevalence of hyperuricaemia markedly increased in women aged above 50 years. The prevalence of hyperuricaemia was significantly higher in metabolically unhealthy participants with normal weight than in metabolically healthy participants with normal weight. Participants with hyperuricaemia showed a higher prevalence of metabolic syndrome and fatty liver disease than participants with normouraemia. Age, waist circumference, estimated glomerular filtration rate, blood urea nitrogen, excessive drinking and fatty liver were associated with hyperuricaemia in both genders. Conclusion: The prevalence of hyperuricaemia was 9.4% in non-obese Chinese adults. Non-obese participants with hyperuricaemia also showed multiple metabolic disorders. We suggest that clinicians pay attention to serum uric acid level in non-obese patients.
- Open Access
- 30 August 2021
- Published by Springer Nature in Environmental Health
- Vol. 20 (1) , 1-11
Associations of acrylamide with non-alcoholic fatty liver disease in American adults: a nationwide cross-sectional study
Background: Acrylamide (AA) is a toxicant to humans, but the association between AA exposure and the risk of non-alcoholic fatty liver disease (NAFLD) remains unclear. In this study, our objective is to examine the cross-sectional association between AA exposure and the risk of NAFLD in American adults. Methods: A total of 3234 individuals who took part in the National Health and Nutrition Examination Survey (NHANES) 2003–2006 and 2013–2016 were enrolled in the study. NAFLD was diagnosed by the U.S. Fatty Liver Index. Multivariable logistic regression models were applied to estimate the association between AA and NAFLD in the whole group and the non-smoking group. Results: We discovered that in the whole group, serum hemoglobin adducts of AA (HbAA) were negatively associated with the prevalence of NAFLD after adjustment for various covariables (P for trend < 0.001). Compared with individuals in the lowest HbAA quartiles, the odds ratios (ORs) with 95% confidence intervals (CIs) in the highest HbAA quartiles were 0.61 (0.46–0.81) and 0.57 (0.36–0.88) in the whole group and the non-smoking group, respectively. In contrast, HbGA/HbAA showed a significantly positive correlation with the prevalence of NAFLD in both groups (P for trend < 0.001). In addition, HbGA was not significantly associated with NAFLD in the whole group or the non-smoking group. Conclusions: HbAA is negatively associated with NAFLD whereas HbGA/HbAA is positively associated with NAFLD in adults in the U.S. Further studies are needed to clarify these relationships.
- 30 August 2021
- Published by Springer Nature in Environmental Health
- Vol. 20 (1) , 1-11
Open AccessAssociations of acrylamide with non-alcoholic fatty liver disease in American adults: a nationwide cross-sectional study
Background: Acrylamide (AA) is a toxicant to humans, but the association between AA exposure and the risk of non-alcoholic fatty liver disease (NAFLD) remains unclear. In this study, our objective is to examine the cross-sectional association between AA exposure and the risk of NAFLD in American adults. Methods: A total of 3234 individuals who took part in the National Health and Nutrition Examination Survey (NHANES) 2003–2006 and 2013–2016 were enrolled in the study. NAFLD was diagnosed by the U.S. Fatty Liver Index. Multivariable logistic regression models were applied to estimate the association between AA and NAFLD in the whole group and the non-smoking group. Results: We discovered that in the whole group, serum hemoglobin adducts of AA (HbAA) were negatively associated with the prevalence of NAFLD after adjustment for various covariables (P for trend < 0.001). Compared with individuals in the lowest HbAA quartiles, the odds ratios (ORs) with 95% confidence intervals (CIs) in the highest HbAA quartiles were 0.61 (0.46–0.81) and 0.57 (0.36–0.88) in the whole group and the non-smoking group, respectively. In contrast, HbGA/HbAA showed a significantly positive correlation with the prevalence of NAFLD in both groups (P for trend < 0.001). In addition, HbGA was not significantly associated with NAFLD in the whole group or the non-smoking group. Conclusions: HbAA is negatively associated with NAFLD whereas HbGA/HbAA is positively associated with NAFLD in adults in the U.S. Further studies are needed to clarify these relationships.
- Open Access
- 4 June 2021
- Published by Wiley in International Journal of Endocrinology
- Vol. 2021, 1-6
Association between High-Density Lipoprotein Cholesterol to Apolipoprotein A-I Ratio and Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study
Background. This study aimed to explore the association between high-density lipoprotein cholesterol to apolipoprotein A-I ratio (HDL-C/apo A-I) and nonalcoholic fatty liver disease (NAFLD). Methods. A total of 9025 Chinese adults were enrolled in this cross-sectional study, who presented their annual health checkups at Zhenhai Lianhua Hospital, Ningbo, during 2017. Results. The NAFLD prevalence was 33.7%, and HDL-C/apo A-I was significantly decreased in NAFLD patients, as well as in lean NAFLD and in patients with NAFLD-related advanced fibrosis (all ). The prevalence of NAFLD and components of metabolic syndrome are inversely associated with HDL-C/apo A-I ( ). Multivariate logistic regression analysis show that HDL-C/apo A-I is inversely associated with the risk of NAFLD (odds ratio: 0.353, 95% confidence interval: 0.257–0.486; ). Conclusions. Our results suggested that increased HDL-C/apo A-I is significantly associated with a decreased risk of NAFLD.
- 4 June 2021
- Published by Wiley in International Journal of Endocrinology
- Vol. 2021, 1-6
Open AccessAssociation between High-Density Lipoprotein Cholesterol to Apolipoprotein A-I Ratio and Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study
Background. This study aimed to explore the association between high-density lipoprotein cholesterol to apolipoprotein A-I ratio (HDL-C/apo A-I) and nonalcoholic fatty liver disease (NAFLD). Methods. A total of 9025 Chinese adults were enrolled in this cross-sectional study, who presented their annual health checkups at Zhenhai Lianhua Hospital, Ningbo, during 2017. Results. The NAFLD prevalence was 33.7%, and HDL-C/apo A-I was significantly decreased in NAFLD patients, as well as in lean NAFLD and in patients with NAFLD-related advanced fibrosis (all ). The prevalence of NAFLD and components of metabolic syndrome are inversely associated with HDL-C/apo A-I ( ). Multivariate logistic regression analysis show that HDL-C/apo A-I is inversely associated with the risk of NAFLD (odds ratio: 0.353, 95% confidence interval: 0.257–0.486; ). Conclusions. Our results suggested that increased HDL-C/apo A-I is significantly associated with a decreased risk of NAFLD.
- 8 February 2021
- Published by Wiley in Liver International
- Vol. 41 (4) , 777-787
Leukocyte cell‐derived chemotaxin 2 promotes the development of nonalcoholic fatty liver disease through STAT‐1 pathway in mice
Background: Nonalcoholic fatty liver disease (NAFLD), whose pathogenesis remains unelucidated, has become an increasingly prevalent disease globally requiring novel treatment strategies. This study aims to explore the role of leukocyte cell‐derived chemotaxin 2 (LECT2), one of the known hepatokines, in the development of NAFLD.Methods: The serum LECT2 level was evaluated in patients with NAFLD and male C57BL/6 mice fed a high‐fat diet (HFD) for 8 weeks. Tail intravenous injection of adeno‐associated virus that contained Lect2 short hairpin RNA or Lect2 overexpression plasmid was administered to mice to inhibit or increase hepatic Lect2 expression. Hepatic steatosis was evaluated by histological staining with haematoxylin and eosin and Oil Red O, and also by quantitative hepatic triglyceride measurements. RNA‐seq was performed to discover the specific targets of LECT2 on NAFLD.Results: Serum and hepatic LECT2 levels were elevated in NAFLD patients and HFD‐fed mice. Inhibition of hepatic Lect2 expression alleviated HFD‐induced hepatic steatosis and inflammation, whereas hepatic overexpression of Lect2 aggravated HFD‐induced hepatic steatosis and inflammation. RNA‐seq and bioinformatical analysis suggested that the signal transducers and activators of transcription‐1 (STAT‐1) pathway might play an indispensable role in the interaction between LECT2 and NAFLD. A STAT‐1 inhibitor could reverse the accumulation of hepatic lipids caused by Lect2 overexpression.Conclusion: LECT2 expression is significantly elevated in NAFLD. LECT2 induces the occurrence and development of NAFLD through the STAT‐1 pathway. LECT2 may be a potential therapeutic target for NAFLD.
- 8 February 2021
- Published by Wiley in Liver International
- Vol. 41 (4) , 777-787
Leukocyte cell‐derived chemotaxin 2 promotes the development of nonalcoholic fatty liver disease through STAT‐1 pathway in mice
Background: Nonalcoholic fatty liver disease (NAFLD), whose pathogenesis remains unelucidated, has become an increasingly prevalent disease globally requiring novel treatment strategies. This study aims to explore the role of leukocyte cell‐derived chemotaxin 2 (LECT2), one of the known hepatokines, in the development of NAFLD.Methods: The serum LECT2 level was evaluated in patients with NAFLD and male C57BL/6 mice fed a high‐fat diet (HFD) for 8 weeks. Tail intravenous injection of adeno‐associated virus that contained Lect2 short hairpin RNA or Lect2 overexpression plasmid was administered to mice to inhibit or increase hepatic Lect2 expression. Hepatic steatosis was evaluated by histological staining with haematoxylin and eosin and Oil Red O, and also by quantitative hepatic triglyceride measurements. RNA‐seq was performed to discover the specific targets of LECT2 on NAFLD.Results: Serum and hepatic LECT2 levels were elevated in NAFLD patients and HFD‐fed mice. Inhibition of hepatic Lect2 expression alleviated HFD‐induced hepatic steatosis and inflammation, whereas hepatic overexpression of Lect2 aggravated HFD‐induced hepatic steatosis and inflammation. RNA‐seq and bioinformatical analysis suggested that the signal transducers and activators of transcription‐1 (STAT‐1) pathway might play an indispensable role in the interaction between LECT2 and NAFLD. A STAT‐1 inhibitor could reverse the accumulation of hepatic lipids caused by Lect2 overexpression.Conclusion: LECT2 expression is significantly elevated in NAFLD. LECT2 induces the occurrence and development of NAFLD through the STAT‐1 pathway. LECT2 may be a potential therapeutic target for NAFLD.
- 11 February 2017
- Published by Wiley in Liver International
- Vol. 37 (8) , 1202-1208
Serum apoB levels independently predict the development of non‐alcoholic fatty liver disease: A 7‐year prospective study
Background & Aims: Cross‐sectional studies have shown that apolipoprotein B (apoB) is positively associated with the prevalence of non‐alcoholic fatty liver disease (NAFLD). This study aimed to investigate the prospective relationship between the serum apoB levels and the development of NAFLD in a Chinese population.Methods: A cohort of 7077 initially NAFLD‐free participants was enrolled in this prospectively study. The incidence of NAFLD was calculated among participants with different baseline serum apoB quintiles. Cox proportional hazards regression analyses were conducted to calculate the risks for incident NAFLD.Results: During 41 555 person‐year follow‐ups, 1139 incident NAFLD cases were identified. The baseline apoB levels were linear and positively correlated with NAFLD incidence. The incidence was 16.99, 22.63, 24.73, 37.51 and 42.77 per 1000 person‐year follow‐up for participants with baseline apoB levels in quintiles 1–5, respectively. Compared with participants with baseline apoB levels in quintile 1, the hazard ratios (95% confidence interval) for incident NAFLD were 1.353 (1.100–1.663), 1.482 (1.207–1.820), 2.232 (1.832–2.720) and 2.543 (2.082–3.106) for participants with baseline apoB levels in quintile 2–5, respectively. The hazard ratios were attenuated but remained statistically significant after adjusting for age, gender, body mass index and variables associated with metabolic syndrome.Conclusion: Elevated serum apoB levels independently predict an increased risk for incident NAFLD.
- 11 February 2017
- Published by Wiley in Liver International
- Vol. 37 (8) , 1202-1208
Serum apoB levels independently predict the development of non‐alcoholic fatty liver disease: A 7‐year prospective study
Background & Aims: Cross‐sectional studies have shown that apolipoprotein B (apoB) is positively associated with the prevalence of non‐alcoholic fatty liver disease (NAFLD). This study aimed to investigate the prospective relationship between the serum apoB levels and the development of NAFLD in a Chinese population.Methods: A cohort of 7077 initially NAFLD‐free participants was enrolled in this prospectively study. The incidence of NAFLD was calculated among participants with different baseline serum apoB quintiles. Cox proportional hazards regression analyses were conducted to calculate the risks for incident NAFLD.Results: During 41 555 person‐year follow‐ups, 1139 incident NAFLD cases were identified. The baseline apoB levels were linear and positively correlated with NAFLD incidence. The incidence was 16.99, 22.63, 24.73, 37.51 and 42.77 per 1000 person‐year follow‐up for participants with baseline apoB levels in quintiles 1–5, respectively. Compared with participants with baseline apoB levels in quintile 1, the hazard ratios (95% confidence interval) for incident NAFLD were 1.353 (1.100–1.663), 1.482 (1.207–1.820), 2.232 (1.832–2.720) and 2.543 (2.082–3.106) for participants with baseline apoB levels in quintile 2–5, respectively. The hazard ratios were attenuated but remained statistically significant after adjusting for age, gender, body mass index and variables associated with metabolic syndrome.Conclusion: Elevated serum apoB levels independently predict an increased risk for incident NAFLD.